Browse the evidence

Tirzepatide 10 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 5.3% to 1.2%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Tirzepatide 15 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 4.9% to 1.0%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Two-thirds of respondents reported reduced appetite, food cravings, or body weight.

Practitioners can expect that a significant portion of patients may experience appetite reduction and weight loss with Ozempic.

Semaglutide (Wegovy) has demonstrated unprecedented efficacy in weight reduction, glycaemic control, and cardiovascular protection.

Semaglutide may be a highly effective treatment option for obesity and type 2 diabetes.

Subcutaneous semaglutide 0.5 mg and subcutaneous liraglutide 3 mg are effective treatments for reducing weight among people with obesity in a real-world scenario after 3 months.

Both semaglutide and liraglutide can be considered effective options for weight management in clinical practice.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide potent weight reduction among persons with overweight/obesity and show cardiovascular benefits.

GLP-1 RAs may be considered as a therapeutic option for weight management in patients with HIV and obesity.

Semaglutide is endorsed as a secondary treatment for improving glycemic control in type 2 diabetes mellitus (T2DM).

Practitioners can consider semaglutide as a secondary option for patients with T2DM to improve blood sugar control.

Semaglutide is being investigated for its potential in combating obesity.

Practitioners should stay informed about the potential use of semaglutide for obesity management.

Semaglutide can help regulate blood sugar levels and decrease long-term health complications related to diabetes.

Practitioners can use semaglutide to manage blood sugar levels and reduce diabetes-related complications.

SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease, independent of diabetes status.

Semaglutide may significantly lower the risk of cardiovascular events in at-risk populations.

Obesity is a significant modifiable risk factor for atrial fibrillation (AF).

Practitioners should focus on managing obesity to reduce the risk of AF.

GLP-1 agonists are approved for weight loss in addition to their original approval for type 2 diabetes.

Healthcare providers should consider GLP-1 agonists for patients needing weight loss support.

GLP-1-based therapies elicit a clinically significant reduction in body weight.

Practitioners can expect GLP-1 therapies to aid in weight loss for patients with type 2 diabetes or obesity.

Tirzepatide reduces appetite and aids in weight reduction management.

Tirzepatide may be effective for patients seeking weight loss.

Tirzepatide is the first dual receptor agonist incorporated into therapeutic recommendations for type 2 diabetes.

Tirzepatide should be considered as a treatment option for type 2 diabetes.

There is a greater emphasis on adjunct pharmacotherapy in the updated guideline, particularly with GLP-1-based agents for weight reduction and improvement of comorbidities.

Healthcare providers should integrate GLP-1-based pharmacotherapy into obesity management strategies.

Binge eating episodes and prevalence reduced following liraglutide and semaglutide.

Practitioners may find liraglutide and semaglutide effective in reducing binge eating behaviors in patients.

PAP+tirzepatide was associated with lower incident PH at 1 year (RR:0.27) and 3 years (RR:0.22), and lower mortality at 1 year (RR:0.14) and 3 years (RR:0.12).

Using tirzepatide in conjunction with PAP may provide superior benefits in reducing PH and mortality for obese patients with OSA.

Compared to PAP+semaglutide, PAP+tirzepatide showed lower incident PH at 1 year (RR:0.51) and 3 years (RR:0.42) and lower all-cause mortality at 1 year (RR:0.41) and 3 years (RR:0.33).

Tirzepatide may offer enhanced benefits over semaglutide for reducing PH and mortality in obese patients with OSA on PAP.

The GLP-1 receptor agonist Semaglutide and the GIPR/GLP-1R co-agonist Tirzepatide lead to a weight loss greater than 10%.

Practitioners can consider Semaglutide and Tirzepatide as effective options for weight management in patients with obesity and Type 2 diabetes.

GLP-1 agonists such as liraglutide and semaglutide are more efficacious than other approved drugs in weight management therapy.

Practitioners may consider GLP-1 agonists as a preferred option for weight management in diabetic patients.

Tirzepatide reduces fasting and postprandial glucose levels, food consumption, and body weight in people with type 2 diabetes.

Tirzepatide may be an effective treatment option for managing blood glucose and weight in type 2 diabetes patients.

Long-acting GLP-1 agonists and incretin multi-agonists have demonstrated clinically significant efficacy in reducing body weight.

Practitioners may consider GLP-1 agonists and incretin multi-agonists as effective options for weight management in obese patients.

GLP-1 based medications can achieve an average weight loss of 24%.

Practitioners can expect significant weight loss with GLP-1 medications.